Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia

7 Jun 2011

Abstract excerpt

PURPOSE: The long-term follow-up results of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy show high cure rates. Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-up results are needed. PATIENTS AND METHODS: One hundred ninety-seven patients with newly diagnosed APL were treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Arsenic contamination and mitigation
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21646615
DOI: 10.1200/jco.2010.32.2107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic LeukemiaPMID 21646615Read ↗

Treatment of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Acute promyelocytic leukemia: from highly fatal to highly curableSemantic proximity Read ↗

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemiaSemantic proximity Read ↗

All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.Semantic proximity Read ↗

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.Semantic proximity Read ↗

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceSemantic proximity Read ↗

Targeted Therapy Alone for Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete RemissionSemantic proximity Read ↗

Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.Semantic proximity Read ↗

Curative Strategies in Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Optimal treatment strategies for high-risk acute promyelocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.